ETFs Akeso, Inc.

9926

KYG0146B1032

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 01:38:03 11/12/2025 pm IST			5-day change	1st Jan Change
117.40 ^HKD	+0.51%		-0.68%	+93.41%

11/12	Akeso, Inc. Announces Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented atESMO IO 2025	CI
09/12	Akeso, Inc. Announces Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia Congress	CI

ETFs positioned on Akeso, Inc.

Name	Weight	AuM	Varia. Jan 1.	Investor
LEADERSHARES EQUITY SKEW ETF - USD	0.03%	51 M€	+4.72%	-
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR INTERNATIONAL ETF - USD	0.01%	32 M€	+26.12%	-
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF	0.01%	33,076 M€	+19.50%	-
RAREVIEW SYSTEMATIC EQUITY ETF - USD	0.01%	51 M€	+19.39%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0%	839 M€	+6.46%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0%	62 M€	+5.78%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR	0%	83 M€	+5.23%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR	0%	619 M€	+6.36%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF ACC - EUR	0%	187 M€	+5.45%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR	0%	33 M€	+3.93%	-
NOMURA NEXT FUNDS EMERGING MARKET EQUITY MSCI-EM (UNHEDGED) ETF - JPY	0%	21 M€	+27.09%	-
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF ACC - EUR	0%	79 M€	+4.45%	-
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF - DISTRIBUTING - EUR	0%	14 M€	+2.69%	-

Akeso Inc is an investment holding company mainly engaged in the research and development, production and commercialization of biopharmaceutical products. The Company is committed to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwide. The Company's products mainly include cadonilimab (PD-1/CTLA-4), Ivonescimab (AK112, PD-1/VEGF), ANNIKO (penpulimab, PD-1), Ebronucimab (AK102, PCSK9) and ebdarokimab (AK101, IL-12/IL-23). The Company's products are principally used to treat tumors, autoimmune diseases, metabolic diseases, as well as neurodegenerative diseases. The Company principally conducts its businesses in Mainland China, the United States and other markets.

Employees

3,529

Sector

Biotechnology & Medical Research

Calendar

01/04 - Q4 2025 Earnings Release (Projected)

More about the company